1731.TW
Maywufa Company Ltd. [1731.TW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1731.TW Stock Summary
Top 10 Correlated ETFs
1731.TW
Top 10 Correlated Stocks
1731.TW
In the News
1731.TW Financial details
Company Rating
Buy
Market Cap
2.92B
Income
162.45M
Revenue
1.27B
Book val./share
15.61
Cash/share
4.52
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
17.64
Forward P/E
-
PEG
-218.74
P/S
2.35
P/B
1.42
P/C
4.89
P/FCF
-129.46
Quick Ratio
2.44
Current Ratio
3.04
Debt / Equity
0.3
LT Debt / Equity
0.2
-
-
EPS (TTM)
1.23
EPS next Y
-
EPS next Q
-
EPS this Y
-1.61%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
16.44%
Revenue last 5Y
2.08%
Revenue Q/Q
-3.7%
EPS Q/Q
-16.67%
-
-
-
-
SMA20
4.76%
SMA50
4.76%
SMA100
-4.35%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
8%
ROC
0.09%
Gross Margin
65%
Oper. Margin
17%
Profit Margin
13%
Payout
-
Shs Outstand
132.92M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
17.9-26.35
52W High
-15%
52W Low
+30%
RSI
58
Rel Volume
2.03
Avg Volume
396.48K
Volume
805.46K
Perf Week
1.84%
Perf Month
5.49%
Perf Quarter
-11.95%
Perf Half Y
-5.35%
-
-
-
-
Beta
0.458106
-
-
Volatility
0.3%, 0.58%
Prev Close
-2%
Price
22.1
Change
-3.07%
1731.TW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.45 | 8.28 | 8.02 | 9.7 | 9.37 | |
| Net income per share | 0.57 | 0.76 | 1.29 | 1.24 | 1.22 | |
| Operating cash flow per share | 1.72 | 1.64 | 1.81 | 1.98 | 1.11 | |
| Free cash flow per share | 1.63 | 1.59 | 0.81 | 1.94 | -0.62 | |
| Cash per share | 1.51 | 5.25 | 6.25 | 6.62 | 4.4 | |
| Book value per share | 12.94 | 13.22 | 14.11 | 15.09 | 15.02 | |
| Tangible book value per share | 12.94 | 13.22 | 14.11 | 15.09 | 15.02 | |
| Share holders equity per share | 12.94 | 13.22 | 14.11 | 15.09 | 15.02 | |
| Interest debt per share | 2.31 | 2.45 | 2.33 | 2.43 | 1.73 | |
| Market cap | 1.64B | 1.77B | 2.32B | 2.6B | 2.63B | |
| Enterprise value | 1.78B | 1.95B | 2.3B | 2.68B | 2.67B | |
| P/E ratio | 21.67 | 17.57 | 13.56 | 15.81 | 16.22 | |
| Price to sales ratio | 1.46 | 1.61 | 2.18 | 2.02 | 2.11 | |
| POCF ratio | 7.19 | 8.13 | 9.65 | 9.88 | 17.75 | |
| PFCF ratio | 7.59 | 8.34 | 21.45 | 10.1 | -31.82 | |
| P/B Ratio | 0.95 | 1.01 | 1.24 | 1.3 | 1.31 | |
| PTB ratio | 0.95 | 1.01 | 1.24 | 1.3 | 1.31 | |
| EV to sales | 1.59 | 1.77 | 2.16 | 2.08 | 2.15 | |
| Enterprise value over EBITDA | 12.14 | 10.88 | 10.77 | 10.82 | 11.17 | |
| EV to operating cash flow | 7.8 | 8.98 | 9.55 | 10.18 | 18.09 | |
| EV to free cash flow | 8.24 | 9.21 | 21.25 | 10.4 | -32.42 | |
| Earnings yield | 0.05 | 0.06 | 0.07 | 0.06 | 0.06 | |
| Free cash flow yield | 0.13 | 0.12 | 0.05 | 0.1 | -0.03 | |
| Debt to equity | 0.55 | 0.56 | 0.32 | 0.34 | 0.27 | |
| Debt to assets | 0.36 | 0.36 | 0.24 | 0.25 | 0.21 | |
| Net debt to EBITDA | 0.95 | 1.03 | -0.1 | 0.32 | 0.21 | |
| Current ratio | 2.29 | 2.38 | 4.24 | 3.62 | 3.36 | |
| Interest coverage | 27.72 | 26.22 | 34.98 | 40.75 | 82.1 | |
| Income quality | 3.02 | 1.61 | 1.16 | 1.24 | 0.71 | |
| Dividend Yield | 0.05 | 0.04 | 0.03 | 0.05 | 0.06 | |
| Payout ratio | 1.05 | 0.66 | 0.47 | 0.81 | 0.96 | |
| Sales general and administrative to revenue | 0.1 | 0.1 | 0.1 | 0.08 | 0.08 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.05 | -0.03 | -0.55 | -0.02 | -1.56 | |
| Capex to revenue | -0.01 | -0.01 | -0.12 | 0 | -0.19 | |
| Capex to depreciation | -0.4 | -0.14 | -3.89 | -0.18 | -7.87 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 12.88 | 15.01 | 20.21 | 20.49 | 20.29 | |
| ROIC | 0.05 | 0.05 | 0.08 | 0.08 | 0.08 | |
| Return on tangible assets | 0.03 | 0.04 | 0.07 | 0.06 | 0.06 | |
| Graham Net | -4.85 | -1.39 | 2.37 | 2.35 | 1.26 | |
| Working capital | 833.42M | 913.77M | 964.52M | 988.65M | 736.53M | |
| Tangible asset value | 1.72B | 1.76B | 1.88B | 2B | 1.99B | |
| Net current asset value | 525.81M | 597.95M | 662.09M | 680.17M | 516.04M | |
| Invested capital | 0.18 | 0.18 | 0.16 | 0.16 | 0.11 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 494.36M | 471.02M | 271.24M | 84.49M | 83.41M | |
| Average inventory | 238.83M | 204.87M | 179.87M | 202.87M | 235.28M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 365.73 | 391.31 | 75.45 | 75.21 | 66.65 | |
| Days of inventory on hand | 165.76 | 162.78 | 157.19 | 202.29 | 197.92 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1 | 0.93 | 4.84 | 4.85 | 5.48 | |
| Inventory turnover | 2.2 | 2.24 | 2.32 | 1.8 | 1.84 | |
| ROE | 0.04 | 0.06 | 0.09 | 0.08 | 0.08 | |
| Capex per share | -0.09 | -0.04 | -1 | -0.04 | -1.73 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.55 | 2.17 | 2.33 | 2.34 | 2.62 | |
| Net income per share | 0.37 | 0.34 | 0.34 | 0.17 | 0.4 | |
| Operating cash flow per share | 0.17 | 0.41 | 0.16 | 0.37 | 0.29 | |
| Free cash flow per share | -0.45 | -0.09 | 0.34 | -0.41 | 0 | |
| Cash per share | 6.37 | 3.79 | 3.98 | 4.43 | 4.52 | |
| Book value per share | 15.46 | 14.36 | 14.87 | 15.13 | 15.61 | |
| Tangible book value per share | 15.46 | 14.36 | 14.87 | 15.13 | 15.61 | |
| Share holders equity per share | 15.46 | 14.36 | 14.87 | 15.13 | 15.61 | |
| Interest debt per share | 2.38 | 0.1 | 1.08 | 1.72 | 1.96 | |
| Market cap | 2.65B | 2.33B | 2.38B | 2.61B | 2.59B | |
| Enterprise value | 2.76B | 2.15B | 2.35B | 2.66B | 2.66B | |
| P/E ratio | 13.35 | 12.83 | 13.24 | 29.63 | 12.28 | |
| Price to sales ratio | 7.82 | 8.03 | 7.72 | 8.44 | 7.5 | |
| POCF ratio | 115.06 | 42.17 | 115.59 | 53.14 | 67.31 | |
| PFCF ratio | -43.77 | -186.9 | 52.95 | -47.85 | -4.28K | |
| P/B Ratio | 1.29 | 1.21 | 1.21 | 1.3 | 1.26 | |
| PTB ratio | 1.29 | 1.21 | 1.21 | 1.3 | 1.26 | |
| EV to sales | 8.16 | 7.4 | 7.64 | 8.6 | 7.72 | |
| Enterprise value over EBITDA | 38.1 | 32.06 | 37.15 | 72.38 | 35.41 | |
| EV to operating cash flow | 120.18 | 38.85 | 114.42 | 54.15 | 69.25 | |
| EV to free cash flow | -45.72 | -172.2 | 52.41 | -48.76 | -4.4K | |
| Earnings yield | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Free cash flow yield | -0.02 | -0.01 | 0.02 | -0.02 | 0 | |
| Debt to equity | 0.31 | 0.24 | 0.22 | 0.27 | 0.3 | |
| Debt to assets | 0.24 | 0.19 | 0.18 | 0.21 | 0.23 | |
| Net debt to EBITDA | 1.62 | -2.74 | -0.38 | 1.35 | 0.99 | |
| Current ratio | 2.12 | 2.18 | 3.46 | 3.36 | 3.04 | |
| Interest coverage | 47.55 | 54.07 | 1.17K | 753.1 | 2.19K | |
| Income quality | 0.36 | 0.94 | 0.37 | 1.65 | 0.57 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.09 | 0.08 | 0.08 | 0.07 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -3.63 | -1.23 | 1.18 | -2.11 | -1.02 | |
| Capex to revenue | -0.25 | -0.23 | 0.08 | -0.34 | -0.11 | |
| Capex to depreciation | -11.31 | -9.24 | 3.35 | -14.15 | -5.34 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 11.39 | 10.48 | 10.67 | 7.53 | 11.85 | |
| ROIC | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Return on tangible assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Graham Net | 2.43 | 1.22 | 1.59 | 1.27 | 0.65 | |
| Working capital | 708.69M | 541.28M | 722.41M | 736.53M | 748.58M | |
| Tangible asset value | 2.05B | 1.92B | 1.96B | 1.99B | 2.05B | |
| Net current asset value | 700.33M | 534.94M | 585.71M | 516.04M | 495.03M | |
| Invested capital | 0.15 | 0.01 | 0.07 | 0.11 | 0.13 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 82.97M | 72.45M | 68.33M | 73.71M | 78.82M | |
| Average inventory | 235.22M | 235.97M | 234.54M | 230.89M | 226.62M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 61.27 | 61.67 | 58.03 | 64.55 | 60.21 | |
| Days of inventory on hand | 183.89 | 218.97 | 192.48 | 191.69 | 167.51 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.47 | 1.46 | 1.55 | 1.39 | 1.49 | |
| Inventory turnover | 0.49 | 0.41 | 0.47 | 0.47 | 0.54 | |
| ROE | 0.02 | 0.02 | 0.02 | 0.01 | 0.03 | |
| Capex per share | -0.63 | -0.51 | 0.18 | -0.78 | -0.3 |
1731.TW Frequently Asked Questions
What is Maywufa Company Ltd. stock symbol ?
Maywufa Company Ltd. is a TW stock and trading under the symbol 1731.TW
What is Maywufa Company Ltd. stock quote today ?
Maywufa Company Ltd. stock price is $22.1 today.
Is Maywufa Company Ltd. stock public?
Yes, Maywufa Company Ltd. is a publicly traded company.
Company Profile
- Volume Average 396.48K
- Market Capitalization 2.92B
- CEO Yi-Li Lee BBA
- Headquarters Taipei,TW
- IPO Date 2000-01-04
-
Website
https://www.maywufa.com.tw 
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. It offers hair care products; health care products and food supplements; and mother and baby skin care products under the mustela brand. The company also provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition. In addition, it sells and distributes pharmaceutical products; and operates and manages pharmacy chain under the Pharmacy Franchise name. Maywufa Company Ltd. was founded in 1976 and is headquartered in Taipei, Taiwan.
